As part of the settlement, CVS admitted and accepted responsibility for certain conduct alleged by the government, including ...

The global insulin analog market size was valued at USD 16.99 billion in 2024 and is predicted to hit around USD 25.29 ...

A record $37.8 million settlement closes a decade-long case alleging that CVS overbilled government health programs by ...

CVS Health Corp. has agreed to pay $37.76 million to resolve a False Claims Act lawsuit alleging that its pharmacies ...

For a decade, CVS knew it was skirting rules meant to limit overprescribing but did nothing to stop, according to the ...

CVS settles insulin dispensing case for $38M over improper billing to Medicare, Medicaid and federal health programs from 2010 to 2020.

CVS has settled a lawsuit for $37.76 million over claims of over-dispensing insulin pens and fraudulent billing.

CVS Health ( CVS) has reached a settlement with the U.S. government, requiring the company to pay $37.76M to resolve claims that it overbilled government healthcare programs for insulin pens.

CVS Health will pay $37.76 million to settle allegations it dispensed too many insulin pens to patients, and then obtained ...

The success of semaglutide and tirzepatide is evident in their 2024 sales volumes and revenues, creating a clearer picture of ...

Aher holds an insulin pen next to his father, Lual, in their home in Ariath, Aweil North, South Sudan. 2025 © Isaac Buay ...

As per SNS Insider Research, North America Leads the Market with 42% Market Share, While Asia Pacific Emerges as the Fastest Growing Region with Strong Adoption of Connected Diabetes ...